CareDx, Inc.
Aug 15, 2017

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif., Aug. 15, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, PhD., Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in four upcoming investor conferences.

Piper Jaffray Bus Tour in Palo Alto, CA

Southern California Investor Conference in Newport Beach, CA

Rodman & Renshaw 19th Annual Global Investment Conference in New York City

Cantor Fitzgerald Global Healthcare Conference in New York City

Live audio webcasts of Southern California Investor, Rodman & Renshaw Global Investment and Cantor Fitzgerald Global Health conferences will be available online from the investor relations page of the Company's website at http://investors.caredxinc.com. The webcast replays of the presentations will begin approximately one hour after the conclusion of the live presentations and will be available on the Company's website for 90 days. Due to the one-on-one only format of the Piper Jaffray Bus Tour, no webcast will be available.

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com

Investor Contact

Sasha King, Chief Commercial Officer

T: +1 415-287-2393

E: sking@caredx.com

Primary Logo

Source: CareDx, Inc.

News Provided by Acquire Media